<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04450680</url>
  </required_header>
  <id_info>
    <org_study_id>BLAST-2</org_study_id>
    <nct_id>NCT04450680</nct_id>
  </id_info>
  <brief_title>Beta-lactam Therapeutic Drug Monitoring in Singapore</brief_title>
  <acronym>BLAST-2</acronym>
  <official_title>A Prospective Cohort Study on Beta-lactam Therapeutic Drug Monitoring in Singapore</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tan Tock Seng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study to evaluate clinical utility and feasibility of
      beta-lactam therapeutic drug monitoring in Singapore. The investigators hypothesise that
      conventional beta-lactam dosing regimens based on manufacturer's recommendations (derived
      from Phase I studies on healthy volunteers) will produce sub-optimal levels in at least half
      of the patients. Hence, beta-lactam therapeutic drug monitoring and dose individualisation
      will be required for optimal clinical outcomes. The investigators' secondary aims include
      correlating various therapeutic targets with clinical outcomes to identify a suitable
      therapeutic target for clinical use and to characterise beta-lactam pharmacokinetics in
      sub-group of patients with complex pharmacokinetics so that local empirical dosing regimens
      can be formulated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite widespread use, conventional beta-lactam dosing regimens, derived from healthy
      volunteers, are sub-optimal clinically as patients display variable pharmacokinetics. This
      problem is further confounded by rising antimicrobial resistance and the need for high dose
      beta-lactams, exceeding licensed recommendations. In order to optimise beta-lactam therapy,
      dose individualisation using therapeutic drug monitoring (TDM) has been suggested. However,
      experience with beta-lactam TDM is limited with varying practices worldwide. Therapeutic
      targets are also variable and have not been extensively validated. Hence, this study
      primarily aims to establish clinical feasibility and utility of beta-lactam TDM. The
      investigators hypothesise that conventional beta-lactam dosing will produce sub-optimal
      levels in at least half of the patients, justifying need for TDM and dose individualisation
      to improve clinical outcomes. The secondary aims include correlating various therapeutic
      targets with clinical outcomes to identify a suitable therapeutic target for clinical use and
      to characterise beta-lactam pharmacokinetics and recommend local empirical dosing regimens.

      The investigators propose a prospective cohort study on adult patients (≥21 years) admitted
      to SGH or TTSH. Four blood samples will be obtained over a dosing interval and assayed using
      liquid chromatography with tandem mass spectrometry. Levels and dose adjustment
      recommendations will be reported to physicians by infectious disease pharmacists.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients achieving beta-lactam therapeutic targets</measure>
    <time_frame>until end of beta-lactam therapy, an average of 2 weeks</time_frame>
    <description>proportion of patients achieving beta-lactam therapeutic targets</description>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Infection, Bacterial</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Beta-lactam Therapeutic Drug Monitoring</intervention_name>
    <description>Monitoring serum beta-lactam levels to individualise beta-lactam doses and ensure therapeutic target attainment</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the above-mentioned hospital and receiving beta-lactam therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (21 years and above)

          -  Admitted to Singapore General Hospital or Tan Tock Seng Hospital

          -  Receiving beta-lactam therapy for documented or suspected infection

          -  Indication for beta-lactam therapeutic drug monitoring: critically ill, altered
             pharmacokinetics (burns, obese, on extracorporeal therapy, dialysis),
             immunocompromised, resistant pathogens, deep-seated infections, suspected or at risk
             for adverse effects

        Exclusion Criteria:

          -  Expected mortality within next 24 hours

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Chua</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Chua</last_name>
    <phone>63213752</phone>
    <email>nathalie.grace.sy.chua@sgh.com.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Kwa</last_name>
    <phone>63266959</phone>
    <email>andrea.kwa.l.h@sgh.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Chua</last_name>
      <phone>63213752</phone>
      <email>nathalie.grace.sy.chua@sgh.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother. 2015 Dec;70(12):3178-83. doi: 10.1093/jac/dkv201. Epub 2015 Jul 17. Review.</citation>
    <PMID>26188037</PMID>
  </reference>
  <reference>
    <citation>Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14.</citation>
    <PMID>24429437</PMID>
  </reference>
  <reference>
    <citation>Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010 Oct;36(4):332-9. doi: 10.1016/j.ijantimicag.2010.06.008. Epub 2010 Aug 3.</citation>
    <PMID>20685085</PMID>
  </reference>
  <reference>
    <citation>Heffernan AJ, Sime FB, Lipman J, Roberts JA. Individualising Therapy to Minimize Bacterial Multidrug Resistance. Drugs. 2018 Apr;78(6):621-641. doi: 10.1007/s40265-018-0891-9. Review.</citation>
    <PMID>29569104</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Singapore General Hospital</investigator_affiliation>
    <investigator_full_name>Nathalie Grace Sy Chua</investigator_full_name>
    <investigator_title>Senior Clinical Pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactams</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT04450680/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

